Recce Pharmaceuticals (ASX:RCE) ended the June quarter with a cash balance of AU$2.9 million, according to a Tuesday filing with the Australian bourse.
The company closed the March quarter with a cash balance of AU$1.7 million, an earlier filing showed.
During the June quarter, Recce saw net cash outflows from operating activities of AU$2.2 million, with research and development accounting for the majority of that spend.
The company's shares gained 1% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.